Medical Marketing and Media - Endo, Novartis begin agreement
ENDO Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel (diclofenac sodium topical gel) 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May with an additional 275 contract sales reps targeting primary care physicians who prescribe both NSAIDs and Cox-2s.
Related Results
Etoricoxib in the Treatment of Osteoarthritis Over 52-Weeks: A Double-Blind, …
Rofecoxib Is Faster and More Effective Than Diclofenac Sodium in Treating Pai…
Endo Licenses U.S. Rights for Voltaren(R) Gel — the First FDA-Approved Topic…
Safe pickings for vultures.
Celebrex labeling updated due to CLASS
Voltaren Gel received FDA approval in October 2007. Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million.-SM
Copyright Haymarket Media, Inc. Apr 2008
Provided by ProQuest Information and Learning Company. All rights Reserved
